Early aggressive intervention in cystic fibrosis: Is it time to redefine our "best practice" strategies?

Chest

Volumn 123, Issue 1, 2003, Pages 1-3

  Fiel, Stanley B ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; DORNASE ALFA; TOBRAMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; CLINICAL TRIAL; CYSTIC FIBROSIS; DATA BASE; DISEASE COURSE; DISEASE EXACERBATION; EDITORIAL; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; INFECTION RISK; LUNG FUNCTION; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0037245981     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.1.1     Document Type: Editorial

References (18)

1. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997; 24:137-142
2. Konstan MW, Hilliard KA, Norvell TM, et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150:448-454
3. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151:1075-1082
4. Dakin CJ, Numa AH, Wang HE, et al. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002; 165:904-910
5. Ranganathan SC, Dezateux C, Bush A, et al. Airway function in infants newly diagnosed with cystic fibrosis. Lancet 2001; 358:1964-1965
6. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30
7. Quan JM, Tiddens HAWM, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139:813-820
8. Stutman HR, Lieberman JM, Nussbaum E, et al. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002; 140:299-305
9. Konstan MW, Byard PH, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-854
10. Eigen H, Rosenstein BJ. A multicenter study of alternate-day prednisone in patients with cystic fibrosis. J Pediatr 1995; 126:515-523
11. Frederiksen B, Lanng S, Koch C, et al. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996; 21:153-158
12. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest 1999; 115:1053-1058
13. Heinzl B, Eber E, Oberwaldner B, et al. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2002; 33:32-37
14. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25:88-92
15. Ratjen F, Döring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358:983-984
16. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patient with cystic fibrosis. Chest 2001; 121:55-63
17. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1991; 179:1190-1196
18. Smith AL, Fiel SB, Mayer-Hamblett N, et al. Lack of association between in vitro antibiotic susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration in cystic fibrosis. Chest 2003 (in press)